{"id":"W3087905898","doi":"10.1016/j.annonc.2020.08.2239","title":"LBA11 IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Puma Biotechnology; Syndax Pharmaceuticals; F. Hoffmann-La Roche; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Atezolizumab; Taxane; Internal medicine; Clinical endpoint; Anthracycline; Cyclophosphamide; Breast cancer; Oncology; Triple-negative breast cancer; Chemotherapy; Phases of clinical research; Placebo; Neoadjuvant therapy; Doxorubicin; Gastroenterology; Surgery; Cancer; Randomized controlled trial; Pathology; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006359616,0.0002733007,0.001435179,0.0002592247,0.00003855812,0.000007614158,0.0003695549,0.000259071,0.0008524531],"category_scores_gemma":[0.0004927294,0.0002299927,0.0001551085,0.0008416207,0.0002574198,0.0001035114,0.0001385812,0.0006432803,0.00001843346],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002133575,"about_ca_system_score_gemma":0.001387034,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.03688357,"about_ca_topic_score_gemma":0.002111186,"domain_scores_codex":[0.9964315,0.0004263084,0.001257653,0.0006484994,0.0006798034,0.0005562467],"domain_scores_gemma":[0.997447,0.0005106478,0.0005370513,0.0004945184,0.0006112172,0.0003996137],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.2199043,0.01836677,0.02730142,0.0001949731,0.001303721,0.001802246,0.1021996,0.00005786593,0.03773342,0.00002254078,0.05241923,0.538694],"study_design_scores_gemma":[0.2977324,0.09119412,0.5245763,0.0009101251,0.0001909289,0.0000439274,0.01176306,0.001303387,0.05085581,0.0003289518,0.02045619,0.0006448172],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9585097,0.0003743471,0.000006980215,0.03688176,0.0001463291,0.001672523,0.0009241092,0.0000297614,0.001454491],"genre_scores_gemma":[0.9961998,0.0009107703,0.0001117271,0.002085073,0.0003181119,0.0001559803,0.00003094532,0.00004503021,0.0001424992],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5380492,"threshold_uncertainty_score":0.9695299,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.16364009510905,"score_gpt":0.4836415677196214,"score_spread":0.3200014726105714,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}